Table 3 Treatment data and clinical outcomes for mismatch repair-deficient sarcomas
From: Characteristics of mismatch repair deficiency in sarcomas
Case | Diagnosis | Location | Treatment | Follow up duration (months) | Pembrolizumab, line of therapy, duration (months) | Outcome |
|---|---|---|---|---|---|---|
1 | Pleomorphic rhabdomyosarcoma | Lower limb | Neoadjuvant chemoradiation | 14 | No | No evidence of disease |
2 | Pleomorphic malignant neoplasm, most suggestive of sarcoma | Anterior Mediastinum | Adjuvant radiation | 13 | No | No evidence of disease |
3 | Malignant epithelioid and spindle cell neoplasm, likely angiosarcoma | Retroperitoneum | Adjuvant chemotherapy | 9 | Yes, 2nd line, (1.5) | Died of disease |
4 | Unclassified sarcoma with epithelioid features | Upper limb | Neoadjuvant radiation | 25 | No | No evidence of disease |
5 | Epithelioid leiomyosarcoma | Uterus | Chemotherapy, radiation, surgery | 61 | Yes, 8th line, (5) | Alive with stable disease |
6 | Malignant PEComa | Uterus | Chemotherapy, radiation, surgery | 45 | Yes, 4th line, (4) | Alive with progressive disease |
7 | Unclassified pleomorphic sarcoma | Back | Neoadjuvant radiation, surgery, chemotherapy | 15 | No | Died of disease |
